Search

Search Constraints

You searched for: Author/Creator Ge, Shili

Search Results

1. A Phase I/II Trial of the Interleukin-6 Receptor–Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients. Issue 11 (November 2015)

2. CLAZAKIZUMAB (ANTI-IL-6 MONOCLONAL) TREATMENT OF PATIENTS WITH CHRONIC & ACTIVE ANTIBODY-MEDIATED REJECTION POST-KIDNEY TRANSPLANTATION (NCT03380377). Issue 3 (September 2020)

3. CLAZAKIZUMAB (ANTI-IL-6) INDUCES FOXP3+ TREGS IN HIGHLY HLA SENSITIZED PATIENTS RECEIVING HLAI KIDNEY TRANSPLANTATION (NCT03380962). Issue 3 (September 2020)

4. Clazakizumab for desensitization in highly sensitized patients awaiting transplantation. Issue 4 (30th December 2021)

5. CLAZAKIZUMAB® (ANTI-IL-6) FOR DESENSITIZATION OF HIGHLY-HLA SENSITIZED PATIENTS AWAITING KIDNEY TRANSPLANT (NCT03380962). Issue 3 (September 2020)

6. Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia. (23rd June 2020)

9. Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients. (6th February 2017)

10. Plasma Exosomes From HLA-Sensitized Kidney Transplant Recipients Contain mRNA Transcripts Which Predict Development of Antibody-Mediated Rejection. Issue 10 (October 2017)